Is reactive thrombocytosis driven by inflammatory cytokines that increase thrombopoietin signaling and platelet production?

Reactive thrombocytosis is a secondary, non-clonal increase in platelet counts (typically >450,000/μL) occurring in response to external physiological stressors rather than intrinsic bone marrow defects. This condition accounts for approximately 80–90% of all cases of thrombocytosis in adults and is characterized by its reversibility once the underlying trigger is addressed.

Mechanistic explanations

The primary driver of reactive thrombocytosis is the cytokine-mediated upregulation of thrombopoietin (TPO).

• The IL-6/Hepatic Axis: Interleukin-6 (IL-6) is the central mediator. During inflammatory states, IL-6 binds to receptors on hepatocytes, activating the JAK1/STAT3 signaling pathway. This leads to the transcriptional upregulation of TPO mRNA in the liver.
• Megakaryocyte Stimulation: Elevated circulating TPO levels bind to the c-Mpl receptor on megakaryocytes in the bone marrow. This stimulates proliferation, maturation, and fragmentation, resulting in increased peripheral platelet production.
• Ancillary Pathways: While IL-6 is the dominant factor, other cytokines such as IL-1, IL-11, and TNF-alpha can synergistically promote megakaryopoiesis, though they often act by further stimulating IL-6 production or enhancing the sensitivity of progenitor cells.

Clinical evidence and implications

Evidence consistently distinguishes reactive processes from primary myeloproliferative neoplasms (MPNs) like essential thrombocythemia.

• Absence of Clonal Markers: Unlike primary disorders, reactive thrombocytosis occurs without driver mutations in JAK2, CALR, or MPL. The bone marrow typically shows normal morphology or simple hypercellularity without the megakaryocyte clustering seen in MPNs.
• Correlation with Inflammation: Serum IL-6 levels have been shown to correlate significantly with both TPO levels and platelet counts in patients with infection, malignancy, or trauma. Clinical studies demonstrate that blocking IL-6 (e.g., with tocilizumab) leads to a rapid normalization of platelet counts, confirming the causal link.
• Risk Profile: Reactive thrombocytosis rarely results in spontaneous thrombosis or hemorrhage unless counts are extreme (>1,000,000/μL), as the platelets produced are functionally normal.

Bottom line

Reactive thrombocytosis is an appropriate physiological response driven by inflammatory cytokines—primarily IL-6—which stimulate hepatic TPO production and increase megakaryocyte activity. It is a diagnosis of exclusion that occurs independently of primary bone marrow disorders and typically resolves with the treatment of the underlying inflammatory condition.